Schroder Investment Management Group decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 7.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 73,124 shares of the company's stock after selling 6,041 shares during the quarter. Schroder Investment Management Group owned about 0.09% of IDEXX Laboratories worth $30,232,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of IDXX. Geode Capital Management LLC grew its stake in shares of IDEXX Laboratories by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company's stock valued at $1,138,732,000 after buying an additional 40,349 shares during the period. Franklin Resources Inc. raised its holdings in shares of IDEXX Laboratories by 2.5% in the 3rd quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company's stock valued at $675,259,000 after purchasing an additional 34,305 shares in the last quarter. Norges Bank acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth about $412,258,000. American Century Companies Inc. increased its stake in IDEXX Laboratories by 30.9% in the fourth quarter. American Century Companies Inc. now owns 809,814 shares of the company's stock valued at $334,810,000 after purchasing an additional 191,385 shares during the last quarter. Finally, Amundi lifted its position in IDEXX Laboratories by 8.1% in the fourth quarter. Amundi now owns 758,669 shares of the company's stock valued at $328,018,000 after acquiring an additional 56,837 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities analysts recently weighed in on the stock. StockNews.com lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Tuesday, March 25th. Barclays boosted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Bank of America boosted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Piper Sandler upped their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Finally, Morgan Stanley cut their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $533.75.
Read Our Latest Research Report on IDXX
IDEXX Laboratories Price Performance
Shares of NASDAQ IDXX traded down $17.03 during midday trading on Friday, reaching $393.73. The company's stock had a trading volume of 1,635,645 shares, compared to its average volume of 591,359. IDEXX Laboratories, Inc. has a one year low of $390.11 and a one year high of $548.88. The company has a market cap of $31.91 billion, a price-to-earnings ratio of 36.90, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a 50 day moving average price of $436.39 and a 200 day moving average price of $441.13. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.
Insider Buying and Selling at IDEXX Laboratories
In other news, EVP George Fennell sold 9,986 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.11% of the company's stock.
About IDEXX Laboratories
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
See Also
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
